Novantrone
(mitoxantrone hydrochloride)Phase 3Small molecule
PfizerMitoxantrone is used to treat certain types of cancer, including leukemia and lymphoma, and is also used to reduce symptoms in patients with multiple sclerosis. It works by damaging cancer cell DNA to stop them from growing and dividing.[1] Novantrone is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Novantrone is one of 156 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.
5
Indications
121
Total Trials
8
Active Trials
155
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Novantrone
PfizerPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Cellcept
RochePhase 3
Busulfex
Akero TherapeuticsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia34 trials
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Completed·—·Phase 1·NCT01127009·3 enrolled
Show 31 more trials
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Completed·—·Phase 1·NCT02070458·30 enrolled
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00052299·472 enrolled
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002719·500 enrolled
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00006122·106 enrolled
Lymphoma15 trials
Show 12 more trials
Metastatic Prostate Cancer9 trials
Show 6 more trials
Leukemia8 trials
Show 5 more trials
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
Completed·—·Phase 1·NCT00003003·29 enrolled
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
Completed·—·Phase 2·NCT00047021·3 enrolled
Breast Cancer7 trials
21 more indications
Acute Lymphoblastic Leukemia7 trials
Prostate Cancer5 trials
Chronic Lymphocytic Leukemia4 trials
Acute Leukemia4 trials
Acute Promyelocytic Leukemia3 trials
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled
Ovarian Cancer3 trials
Myelodysplastic Syndromes3 trials
Myelodysplastic Syndrome3 trials
Bone Marrow Transplantation2 trials
Myeloid Neoplasm2 trials
Chronic Myelogenous Leukemia2 trials
Thyroid Cancer1 trial
Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery
Not yet recruiting·—·Phase 4·NCT07354698·114 enrolled
Chemotherapy1 trial
Ovarian Epithelial Cancer1 trial
Newly Diagnosed1 trial
Kaposi's sarcoma1 trial
Juvenile Myelomonocytic Leukemia1 trial
Multiple Myeloma1 trial
Hematologic Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mitoxantrone hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]